Le Lézard
Classified in: Health, Science and technology
Subject: PLW

Inhalis Therapeutics SA Achieves Key Milestone with Patent Application Filing


LUGANO, Switzerland, Aug. 21, 2023 /PRNewswire/ -- Inhalis Therapeutics SA, a pioneering privately-held company specializing in advanced inhaled treatments for life-threatening diseases, proudly reveals a significant stride forward as it submits a new patent application on INHAL-101, its lead asset. This strategic move strengthens the company's positioning and enriches its intellectual property portfolio.

Inhalis Therapeutics Logo

Dr. Silvia Panigone, CEO of Inhalis Therapeutics, expressed her enthusiasm, stating, "The achievement of this pivotal milestone marks a moment of great pride for Inhalis. Our dedicated team has been steadfastly committed to developing INHAL-101, a unique small-molecule PI3K/mTOR/BRD4 tri-specific inhibitor. This ground-breaking formulation employs proprietary mSAS® supercritical fluid technology, demonstrating a compelling profile for addressing the complex challenges of Idiopathic Pulmonary Fibrosis (IPF). By selectively inhibiting the key IPF-driven pathogenic elements through a single inhalable medication, with excellent safety potential, INHAL-101 offers an opportunity to harness its full pharmacological power to be an efficacious and well-tolerated drug. This recent patent application strengthens our competitive positioning and provides additional value for Inhalis. We remain dedicated to our journey, and most importantly, to those people afflicted by IPF who stand to benefit from our unwavering commitment."

About Inhalis Therapeutics SA

Inhalis Therapeutics SA is committed to develop breakthrough inhaled treatments for life-threatening disorders. Solid science and industry-leading delivery technology are combined with an experienced management team to research and develop new inhaled treatments for Idiopathic Pulmonary Fibrosis and other diseases. The lead asset, INHAL-101, a ground-breaking solution for IPF, is poised to initiate clinical trials in Q4/2024. The company's pipeline also includes INHAL-102, tailored for lung cancer, and additional assets in late-preclinical proof-of-concept stages for oncology, fibrotic diseases and pulmonary infections.

For further information, please contact:

Silvia Panigone, PhD, EMBA
Chief Executive Officer
Inhalis Therapeutics SA
Phone: +41 78 89 89 644
Email: [email protected] 

Logo - https://mma.prnewswire.com/media/2189259/Inhalis_Therapeutics_Logo.jpg


These press releases may also interest you

at 18:45
SHATTERPROOF AND ANTHEM BLUE CROSS AND BLUE SHIELD FOUNDATION PARTNER TO REDUCE HEALTHCARE STIGMA AROUND A SUBSTANCE USE DISORDER
A substance use disorder (SUD) is a complex and often stigmatized health condition that affects countless individuals, families and communities. Stigma against people with a SUD extends beyond individual and interpersonal levels. The Shatterproof...

at 18:35
AARP Responds to 2024 Medicare and Social Security Trustees Reports
AARP CEO Jo Ann Jenkins issued the following statement in response to the Medicare and Social Security Trustees Reports released today:...

at 18:35
NUTEX HEALTH ANNOUNCES INTERNET AVAILABILITY OF PROXY MATERIALS FOR ITS 2024 ANNUAL MEETING
Nutex Health Inc. ("Nutex Health" or the "Company") , a physician-led, technology-enabled integrated healthcare delivery system comprised of 21 state-of-the-art micro hospitals in 9 states and primary care-centric, risk-bearing physician networks,...

at 18:28
Illumina publicly files Form 10 registration statement ahead of planned divestiture of GRAIL
Illumina, Inc. today announced that it has publicly filed a Form 10 registration statement with the U.S. Securities and Exchange Commission ("SEC"), in connection with its intended divestiture of GRAIL. A version of this registration statement was...

at 18:06
New research confirms that Beethoven had lead poisoning -- but it didn't kill him
To this day, no one knows for certain what caused the liver and kidney disease that led to Ludwig van Beethoven's untimely death. However, a new letter to the editor in the Association for Diagnostics & Laboratory Medicine's (ADLM's, formerly AACC's)...

at 18:00
Secretary of State Antony J. Blinken Tours Antheia, Discusses the Importance of Biotechnology Innovation in the United States
Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, today hosted Secretary of State Antony J. Blinken for a tour of its state of the art labs, as well as a discussion on biotechnology innovation and...

More news about Health...


News published on and distributed by: